American Journal of Kidney Diseases
Volume 53, Issue 1 , Pages 151-165 , January 2009

Obesity Management in Adults With CKD

  • Holly Kramer, MD, MPH

      Affiliations

    • Department of Preventive Medicine, Division of Nephrology and Hypertension, Loyola Medical Center, Maywood, IL
    • Department of Medicine, Division of Nephrology and Hypertension, Loyola Medical Center, Maywood, IL
    • Corresponding Author InformationAddress correspondence to Holly Kramer, MD, MPH, Department of Preventive Medicine, Loyola University Medical Center, 2160 First Ave, Maywood, IL 60153
    • ,
  • Katherine R. Tuttle, MD

      Affiliations

    • Providence Medical Research Center, Sacred Heart Medical Center, University of Washington School of Medicine, Spokane, WA
    • ,
  • David Leehey, MD

      Affiliations

    • Department of Medicine, Division of Nephrology and Hypertension, Loyola Medical Center, Maywood, IL
    • ,
  • Amy Luke, PhD

      Affiliations

    • Department of Preventive Medicine, Division of Nephrology and Hypertension, Loyola Medical Center, Maywood, IL
    • ,
  • Ramon Durazo-Arvizu, PhD

      Affiliations

    • Department of Preventive Medicine, Division of Nephrology and Hypertension, Loyola Medical Center, Maywood, IL
    • ,
  • David Shoham, PhD

      Affiliations

    • Department of Preventive Medicine, Division of Nephrology and Hypertension, Loyola Medical Center, Maywood, IL
    • ,
  • Richard Cooper, MD

      Affiliations

    • Department of Preventive Medicine, Division of Nephrology and Hypertension, Loyola Medical Center, Maywood, IL
    • ,
  • Srinvisan Beddhu, MD

      Affiliations

    • Medical Service, Salt Lake VA Healthcare System, Division of Nephrology and Hypertension, University of Utah School of Medicine, Salt Lake City, UT

References 

  1. Office of the Surgeon General. In: The Surgeon General's Call to Action to Prevent and Decrease Overweight and Obesity. 2001;Rockville, MD, US Department of Health and Human Services PHS; Washington DC, US Government Printing Office
  2. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289:76–79
  3. Wang Y, Chen X, Song Y, Caballero B, Cheskin LJ. Association between obesity and kidney disease: A systematic review and meta-analysis. Kidney Int. 2008;73:19–33
  4. Griffin KA, Kramer H, Bidani AK. Adverse renal consequences of obesity. Am J Physiol Renal Physiol. 2008;294:F685–F696
  5. Kuczmarski RJ, Flegal KM. Criteria for definition of overweight in transition: Background and recommendations for the United States. Am J Clin Nutr. 2000;72:1074–1081
  6. Harvey KS. Methods for determining healthy body weight in end stage renal disease. J Ren Nutr. 2006;16:269–276
  7. Nutrition and Your Health: Dietary Guidelines for Americans. Washington DC: US Department of Agriculture and US Department of Health and Human Services; 1995;
  8. WHO. Obesity: Preventing and Managing the Global Epidemic: Report of a WHO Consultation on Obesity, Geneva, June 3-5, 1997. Geneva, Switzerland: World Health Organization; 1998;
  9. Durazo-Arvizu RA, McGee DL, Cooper RS, Liao Y, Luke A. Mortality and optimal body mass index in a sample of the US population. Am J Epidemiol. 1998;147:739–749
  10. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med. 1999;341:1097–1105
  11. Andres R, Elahi D, Tobin JD, Muller DC, Brant L. Impact of age on weight goals. Ann Intern Med. 1985;103:1030–1033
  12. Stevens J, Cai J, Pamuk ER, Williamson DF, Thun MJ, Wood JL. The effect of age on the association between body-mass index and mortality. N Engl J Med. 1998;338:1–7
  13. Grabowski DC, Ellis JE. High body mass index does not predict mortality in older people: Analysis of the Longitudinal Study of Aging. J Am Geriatr Soc. 2001;49:968–979
  14. Stevens J, Cai J, Juhaeri , Thun MJ, Williamson DF, Wood JL. Consequences of the use of different measures of effect to determine the impact of age on the association between obesity and mortality. Am J Epidemiol. 1999;150:399–407
  15. Adams KF, Schatzkin A, Harris TB, et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med. 2006;355:763–778
  16. Fontaine KR, Redden DT, Wang C, Westfall AO, Allison DB. Years of life lost due to obesity. JAMA. 2003;289:187–193
  17. Peeters A, Barendregt JJ, Willekens F, Mackenbach JP, Al Mamun A, Bonneux L. Obesity in adulthood and its consequences for life expectancy: A life-table analysis. Ann Intern Med. 2003;138:24–32
  18. Heiat A, Vaccarino V, Krumholz HM. An evidence-based assessment of federal guidelines for overweight and obesity as they apply to elderly persons. Arch Intern Med. 2001;161:1194–1203
  19. Abell JE, Egan BM, Wilson PW, Lipsitz S, Woolson RF, Lackland DT. Differences in cardiovascular disease mortality associated with body mass between black and white persons. Am J Public Health. 2008;98:63–66
  20. Durazo-Arvizu R, Cooper RS, Luke A, Prewitt TE, Liao Y, McGee DL. Relative weight and mortality in U.S. blacks and whites: Findings from representative national population samples. Ann Epidemiol. 1997;7:383–395
  21. Bigaard J, Frederiksen K, Tjonneland A, et al. Waist circumference and body composition in relation to all-cause mortality in middle-aged men and women. Int J Obes. 2005;29:778–784
  22. Rankinen T, Kim SY, Perusse L, Despres JP, Bouchard C. The prediction of abdominal visceral fat level from body composition and anthropometry: ROC analysis. J Int Assoc Stud Obes. 1999;23:801–809
  23. Reeder BA, Senthilselvan A, Despres JP, et al. The association of cardiovascular disease risk factors with abdominal obesity in Canada (Canadian Heart Health Surveys Research Group). CMAJ. 1997;157(suppl 1):S39–S45
  24. Pouliot MC, Despres JP, Lemieux S, et al. Waist circumference and abdominal sagittal diameter: Best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol. 1994;73:460–468
  25. Janssen I, Katzmarzyk PT, Ross R. Body mass index, waist circumference, and health risk: Evidence in support of current National Institutes of Health guidelines. Arch Intern Med. 2002;162:2074–2079
  26. Balkau B, Deanfield JE, Despres JP, et al. International Day for the Evaluation of Abdominal Obesity (IDEA): A study of waist circumference, cardiovascular disease, and diabetes mellitus in 168,000 primary care patients in 63 countries. Circulation. 2007;116:1942–1951
  27. Lean ME, Han TS, Morrison CE. Waist circumference as a measure for indicating need for weight management. BMJ. 1995;311:158–161
  28. Narisawa S, Nakamura K, Kato K, Yamada K, Sasaki J, Yamamoto M. Appropriate waist circumference cutoff values for persons with multiple cardiovascular risk factors in Japan: A large cross-sectional study. J Epidemiol. 2008;18:37–42
  29. Koster A, Leitzmann MF, Schatzkin A, et al. Waist circumference and mortality. Am J Epidemiol. 2008;167:1465–1475
  30. Zhang C, Rexrode KM, van Dam RM, Li TY, Hu FB. Abdominal obesity and the risk of all-cause, cardiovascular, and cancer mortality: Sixteen years of follow-up in US women. Circulation. 2008;117:1658–1667
  31. Chen J, Muntner P, Hamm LL, et al. Insulin resistance and risk of chronic kidney disease in nondiabetic US adults. J Am Soc Nephrol. 2003;14:469–477
  32. Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med. 2004;140:167–174
  33. Kramer H, Luke A, Bidani A, Cao G, Cooper R, McGee D. Obesity and prevalent and incident chronic kidney disease: The Hypertension Detection and Follow-up Program. Am J Kidney Dis. 2005;46:587–594
  34. Hsu CY, McCulloch CE, Iribarren C, Darbinian J, Go AS. Body mass index and risk for end-stage renal disease. Ann Intern Med. 2006;144:21–28
  35. Gelber RP, Kurth T, Kausz AT, et al. Association between body mass index and CKD in apparently healthy men. Am J Kidney Dis. 2005;46:871–880
  36. Sanches F, Avesani C, Kamimura M, et al. Waist circumference and visceral fat in CKD: A cross-sectional study. Am J Kidney Dis. 2008;52:66–73
  37. Elsayed EF, Tighiouart H, Weiner DE, et al. Waist-to-hip ratio and body mass index as risk factors for cardiovascular events in CKD. Am J Kidney Dis. 2008;52:49–57
  38. Kwan BC, Murtaugh MA, Beddhu S. Associations of body size with metabolic syndrome and mortality in moderate chronic kidney disease. Clin J Am Soc Nephrol. 2007;2:992–998
  39. Madero M, Sarnak MJ, Wang X, et al. Body mass index and mortality in CKD. Am J Kidney Dis. 2007;50:404–411
  40. Leavey SF, McCullough K, Hecking E, Goodkin D, Port FK, Young EW. Body mass index and mortality in ‘healthier’ as compared with ‘sicker’ haemodialysis patients: Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2001;16:2386–2394
  41. Fleischmann E, Teal N, Dudley J, May W, Bower JD, Salahudeen AK. Influence of excess weight on mortality and hospital stay in 1346 hemodialysis patients. Kidney Int. 1999;55:1560–1567
  42. Johansen KL, Young B, Kaysen GA, Chertow GM. Association of body size with outcomes among patients beginning dialysis. Am J Clin Nutr. 2004;80:324–332
  43. Kalantar-Zadeh K, Kopple JD, Kilpatrick RD, et al. Association of morbid obesity and weight change over time with cardiovascular survival in hemodialysis population. Am J Kidney Dis. 2005;46:489–500
  44. Kalantar-Zadeh K. Obesity paradox in patients on maintenance dialysis. In:  Wolf G editors. Obesity and the Kidney. Basel, Switzerland: Karger; 2006;p. 57–69
  45. Beddhu S, Pappas LM, Ramkumar N, Samore M. Effects of body size and body composition on survival in hemodialysis patients. J Am Soc Nephrol. 2003;14:2366–2372
  46. Beddhu S. The body mass index paradox and an obesity, inflammation, and atherosclerosis syndrome in chronic kidney disease. Semin Dial. 2004;17:229–232
  47. Kakiya R, Shoji T, Tsujimoto Y, et al. Body fat mass and lean mass as predictors of survival in hemodialysis patients [see comment]. Kidney Int. 2006;70:549–556
  48. Kalantar-Zadeh K, Kuwae N, Wu DY, et al. Associations of body fat and its changes over time with quality of life and prospective mortality in hemodialysis patients. Am J Clin Nutr. 2006;83:202–210
  49. Lindsted KD, Singh PN. Body mass and 26-year risk of mortality among women who never smoked: Findings from the Adventist Mortality Study. Am J Epidemiol. 1997;146:1–11
  50. McGee DL Diverse Populations Collaboration. Body mass index and mortality: A meta-analysis based on person-level data from twenty-six observational studies. Ann Epidemiol. 2005;15:87–97
  51. de Mutsert R, Snijder MB, van der Sman-de Beer F, et al. Association between body mass index and mortality is similar in the hemodialysis population and the general population at high age and equal duration of follow-up. J Am Soc Nephrol. 2007;18:967–974
  52. Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease: Pathophysiology, evaluation, and effect of weight loss: An update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2006;113:898–918
  53. Orchard TJ, Temprosa M, Goldberg R, et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: The Diabetes Prevention Program randomized trial. Ann Intern Med. 2005;142:611–619
  54. Chagnac A, Weinstein T, Herman M, Hirsh J, Gafter U, Ori Y. The effects of weight loss on renal function in patients with severe obesity. J Am Soc Nephrol. 2003;14:1480–1486
  55. Morales E, Valero MA, Leon M, Hernandez E, Praga M. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis. 2003;41:319–327
  56. National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease (Guideline 5: Nutritional management in diabetes and chronic kidney disease). Am J Kidney Dis. 2007;49(suppl 2):S95–S107
  57. Snow V, Barry P, Fitterman N, Qaseem A, Weiss K Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Pharmacologic and surgical management of obesity in primary care: A clinical practice guideline from the American College of Physicians. Ann Intern Med. 2005;142:525–531
  58. Bagby SP. Obesity-initiated metabolic syndrome and the kidney: A recipe for chronic kidney disease?. J Am Soc Nephrol. 2004;15:2775–2791
  59. Bantle JP, Wylie-Rosett J, Albright AL, et al. Nutrition recommendations and interventions for diabetes: A position statement of the American Diabetes Association. Diabetes Care. 2008;31(suppl 1):S61–S78
  60. Kahraman S, Yilmaz R, Akinci D, et al. U-Shaped association of body mass index with inflammation and atherosclerosis in hemodialysis patients. J Ren Nutr. 2005;15:377–386
  61. Odamaki M, Furuya R, Ohkawa S, et al. Altered abdominal fat distribution and its association with the serum lipid profile in non-diabetic haemodialysis patients. Nephrol Dial Transplant. 1999;14:2427–2432
  62. Yamauchi T, Kuno T, Takada H, Nagura Y, Kanmatsuse K, Takahashi S. The impact of visceral fat on multiple risk factors and carotid atherosclerosis in chronic haemodialysis patients. Nephrol Dial Transplant. 2003;18:1842–1847
  63. Lichtenstein AH, Appel LJ, Brands M, et al. American Heart Association Nutrition Committee Diet and lifestyle recommendations revision 2006: A scientific statement from the American Heart Association Nutrition Committee [erratum in Circulation 114:e629, 2006]. Circulation. 2006;114:82–96
  64. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, classification and stratification (Part 4. Definition and classification of stages of chronic kidney disease). Am J Kidney Dis. 2002;39(suppl 1):S72–S75
  65. Axelsson J, Rashid Qureshi A, Suliman ME, et al. Truncal fat mass as a contributor to inflammation in end-stage renal disease. Am J Clin Nutr. 2004;80:1222–1229
  66. Hung CY, Chen YA, Chou CC, Yang CS. Nutritional and inflammatory markers in the prediction of mortality in Chinese hemodialysis patients. Nephron. 2005;100:c20–c26
  67. Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis. 2000;35:469–476
  68. Beddhu S, Ramkumar N, Samore MH. The paradox of the “body mass index paradox” in dialysis patients: Associations of adiposity with inflammation. Am J Clin Nutr. 2005;82:909–910
  69. Stenvinkel P, Lindholm B. Resolved: Being fat is good for dialysis patients: The Godzilla effect: Con. J Am Soc Nephrol. 2008;19:1062–1064
  70. Rabbat CG, Thorpe KE, Russell JD, Churchill DN. Comparison of mortality risk for dialysis patients and cadaveric first renal transplant recipients in Ontario, Canada. J Am Soc Nephrol. 2000;11:917–922
  71. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999;341:1725–1730
  72. Gore JL, Pham PT, Danovitch GM, et al. Obesity and outcome following renal transplantation. Am J Transplant. 2006;6:357–363
  73. Meier-Kriesche HU, Arndorfer JA, Kaplan B. The impact of body mass index on renal transplant outcomes: A significant independent risk factor for graft failure and patient death. Transplantation. 2002;73:70–74
  74. Jindal RM, Zawada ET. Obesity and kidney transplantation. Am J Kidney Dis. 2004;43:943–952
  75. Johnson DW, Isbel NM, Brown AM, et al. The effect of obesity on renal transplant outcomes. Transplantation. 2002;74:675–681
  76. Kalil RS, Hunsicker LG. The disadvantage of being fat [comment]. J Am Soc Nephrol. 2008;19:191–193
  77. Chang SH, Coates PT, McDonald SP. Effects of body mass index at transplant on outcomes of kidney transplantation. Transplantation. 2007;84:981–987
  78. Pelletier SJ, Maraschio MA, Schaubel DE, et al. Survival benefit of kidney and liver transplantation for obese patients on the waiting list. Clin Transplants. 2003;77–88
  79. Glanton CW, Kao TC, Cruess D, Agodoa LY, Abbott KC. Impact of renal transplantation on survival in end-stage renal disease patients with elevated body mass index. Kidney Int. 2003;63:647–653
  80. Eckel RH. Clinical practice (Nonsurgical management of obesity in adults). N Engl J Med. 2008;358:1941–1950
  81. Packard DP, Milton JE, Shuler LA, Short RA, Tuttle KR. Implications of chronic kidney disease for dietary treatment in cardiovascular disease. J Ren Nutr. 2006;16:259–268
  82. Moinuddin I, Leehey DJ. A comparison of aerobic exercise and resistance training in patients with and without chronic kidney disease. Adv Chronic Kidney Dis. 2008;15:83–96
  83. Patel MG. The effect of dietary intervention on weight gains after renal transplantation. J Ren Nutr. 1998;8:137–141
  84. Guida B, Trio R, Laccetti R, et al. Role of dietary intervention on metabolic abnormalities and nutritional status after renal transplantation. Nephrol Dial Transplant. 2007;22:3304–3310
  85. Kennedy ET, Bowman SA, Spence JT, Freedman M, King J. Popular diets: Correlation to health, nutrition, and obesity. J Am Diet Assoc. 2001;101:411–420
  86. Friedman AN. High-protein diets: Potential effects on the kidney in renal health and disease. Am J Kidney Dis. 2004;44:950–962
  87. Uribarri J, Tuttle KR. Advanced glycation end products and nephrotoxicity of high-protein diets. Clin J Am Soc Nephrol. 2006;1:1293–1299
  88. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Nutrition in Chronic Renal Failure. Am J Kidney Dis. 2000;35(suppl 2):S1–S140
  89. Li Z, Maglione M, Tu W, et al. Meta-analysis: Pharmacologic treatment of obesity. Ann Intern Med. 2005;142:532–546
  90. Bray GA, Greenway FL. Pharmacological treatment of the overweight patient. Pharmacol Rev. 2007;59:151–184
  91. FDA. Briefing Document (NDA 21-888 Zimulti (rimonabant) Tablets, 20 mg Sanofi Aventis Advisory Committee 2007). http://www.fda.gov/ohrms/dockets/AC/07/briefing/2007-4306b1-fda-backgrounder.pdfAccessed August 18, 2008
  92. Henness S, Perry CM. Orlistat: A review of its use in the management of obesity. Drugs. 2006;66:1625–1656
  93. Finer N, James WP, Kopelman PG, Lean ME, Williams G. One-year treatment of obesity: A randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. J Int Assoc Stud Obes. 2000;24:306–313
  94. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of Diabetes in Obese Subjects (XENDOS) Study: A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27:155–161
  95. Nagele H, Petersen B, Bonacker U, Rodiger W. Effect of orlistat on blood cyclosporin concentration in an obese heart transplant patient. Eur J Clin Pharmacol. 1999;55:667–669
  96. Zhi J, Moore R, Kanitra L, Mulligan TE. Pharmacokinetic evaluation of the possible interaction between selected concomitant medications and orlistat at steady state in healthy subjects. J Clin Pharmacol. 2002;42:1011–1019
  97. Kelley DE, Kuller LH, McKolanis TM, Harper P, Mancino J, Kalhan S. Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes. Diabetes Care. 2004;27:33–40
  98. Singh A, Sarkar SR, Gaber LW, Perazella MA. Acute oxalate nephropathy associated with orlistat, a gastrointestinal lipase inhibitor. Am J Kidney Dis. 2007;49:153–157
  99. Phurrough S, Salive M, Brechner R, Tillman K, Harrison S, O'Connor D. Decision Memo for Bariatric Surgery for the Treatment of Morbid Obesity 2006. http://www.cms.hhs.gov/mcd/viewdecisionmemo.asp?id=160Accessed November 7, 2008
  100. Consensus Development Conference Panel. NIH conference: Gastrointestinal surgery for severe obesity. Ann Intern Med. 1991;115:956–961
  101. Flum DR, Salem L, Elrod JA, Dellinger EP, Cheadle A, Chan L. Early mortality among Medicare beneficiaries undergoing bariatric surgical procedures. JAMA. 2005;294:1903–1908
  102. Bouldin M, Ross L, Sumrall C, Loustalot F, Low A, Land K. The effect of obesity surgery on obesity comorbidity. Am J Med Sci. 2006;331:183–193
  103. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: A systematic review and meta-analysis. JAMA. 2004;292:1724–1737
  104. Sjostrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351:2683–2693
  105. Anderson J, Konz E. Obesity and disease management: Effects of weight loss on co-morbid conditions. Obes Res. 2001;9(suppl 11):S326–S334
  106. Flum DR, Dellinger EP. Impact of gastric bypass operation on survival: A population-based analysis. J Am Coll Surg. 2004;199:543–551
  107. Sjostrom L, Narbro K, Sjostrom CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357:741–752
  108. Eleftheriadis T, Antoniadi G, Liakopoulos V, Kartsios C, Stefanidis I. Disturbances of acquired immunity in hemodialysis patients. Semin Dial. 2007;20:440–451
  109. Livingston EH, Langert J. The impact of age and Medicare status on bariatric surgical outcomes. Arch Surg. 2006;141:1115–1120
  110. Christou NV, Sampalis JS, Liberman M, et al. Surgery decreases long-term mortality, morbidity, and health care use in morbidly obese patients. Ann Surg. 2004;240:416–423
  111. Asplin JR, Coe FL. Hyperoxaluria in kidney stone formers treated with modern bariatric surgery. J Urol. 2007;177:565–569
  112. Nasr SH, D'Agati V, Said SM, et al. Oxalate nephropathy complicating Roux-en-Y gastric bypass: An underrecognized cause of irreversible renal failure. Clin J Am Soc Nephrol. 2008;Aug 13 [Epub ahead of print]
  113. Sinha MK, Collazo-Clavell ML, Rule A, et al. Hyperoxaluric nephrolithiasis is a complication of Roux-en-Y gastric bypass surgery. Kidney Int. 2007;72:100–107
  114. Nelson WK, Houghton SG, Milliner DS, Lieske JC, Sarr MG. Enteric hyperoxaluria, nephrolithiasis, and oxalate nephropathy: Potentially serious and unappreciated complications of Roux-en-Y gastric bypass. Surg Obes Relat Dis. 2005;1:481–485
  115. Bernhardt WM, Schefold JC, Weichert W, et al. Amelioration of anemia after kidney transplantation in severe secondary oxalosis. Clin Nephrol. 2006;65:216–221
  116. Thakar CV, Kharat V, Blanck S, Leonard AC. Acute kidney injury after gastric bypass surgery. Clin J Am Soc Nephrol. 2007;2:426–430
  117. Koshy A. Laparoscopic gastric banding surgery performed in obese dialysis patients prior to kidney transplantation. Am J Kidney Dis. 2008;52:e15–e17
  118. Soto FC, Higa-Sansone G, Copley JB, et al. Renal failure, glomerulonephritis and morbid obesity: Improvement after rapid weight loss following laparoscopic gastric bypass. Obes Surg. 2005;15:137–140
  119. Newcombe V, Blanch A, Slater GH, Szold A, Fielding GA. Laparoscopic adjustable gastric banding prior to renal transplantation. Obes Surg. 2005;15:567–570
  120. Alexander JW, Goodman H. Gastric bypass in chronic renal failure and renal transplant. Nutr Clin Pract. 2007;22:16–21
  121. Petry NM, Barry D, Pietrzak RH, Wagner JA. Overweight and obesity are associated with psychiatric disorders: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychosom Med. 2008;70:288–297
  122. Schowalter M, Benecke A, Lager C, et al. Changes in depression following gastric banding: A 5- to 7-year prospective study. Obes Surg. 2008;18:314–320
  123. Onyike CU, Crum RM, Lee HB, Lyketsos CG, Eaton WW. Is obesity associated with major depression? (Results from the Third National Health and Nutrition Examination Survey). Am J Epidemiol. 2003;158:1139–1147
  124. Wadden TA, Sarwer DB, Fabricatore AN, Jones L, Stack R, Williams NS. Psychosocial and behavioral status of patients undergoing bariatric surgery: What to expect before and after surgery. Med Clin North Am. 2007;91:451–469
  125. Dixon JB, Dixon ME, O'Brien PE. Depression in association with severe obesity: Changes with weight loss. Arch Intern Med. 2003;163:2058–2065
  126. Emery CF, Fondow MD, Schneider CM, et al. Gastric bypass surgery is associated with reduced inflammation and less depression: A preliminary investigation. Obes Surg. 2007;17:759–763

PII: S0272-6386(08)01472-8

doi: 10.1053/j.ajkd.2008.10.003

American Journal of Kidney Diseases
Volume 53, Issue 1 , Pages 151-165 , January 2009

Article Tools

* Image Usage & Resolution